Sign inJoin waitlistJoin the waitlist

AH

Alex Herrera

Associate Medical Director of the Briskin Center for Clinical Research · City of Hope National Medical Center

Credentials: · · · · ·

History

Briskin Center for Clinical Research · City of Hope National Medical Center
Present
Lymphoma Fellowship Program · City of Hope National Medical Center
Present
Division of Lymphoma · City of Hope National Medical Center
Present

City of Hope National Medical Center
2014–2015
Hematology and Medical Oncology
Dana-Farber Cancer Institute
2012–2014
Internal Medicine
Brigham and Women's Hospital
2009–2012
Harvard Medical School
2005–2009
Princeton University
2003

Research

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
The Lancet Oncology · 2019 · 1,921 citations
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology · 2020 · 647 citations
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
Blood · 2023 · 409 citations

MM
Matthew Mei
46 papers
Philippe Armand
39 papers
Stephen Forman
33 papers
Leslie Popplewell
32 papers
Joo Song
29 papers
Elizabeth Budde
28 papers
Geoffrey Shouse
27 papers
Mazyar Shadman
27 papers
Reid Merryman
24 papers · 6 as a fellow
Craig Sauter
23 papers
Mohamed Dabaja
23 papers
LK
Larry Kwak
22 papers

Grants

Leading NCI Clinical Trials Network Research Nationally and at the City of Hope Comprehensive Cancer Center
National Cancer Institute · R50
Contact PI · $624.3K · Beckman Research Institute/City of Hope
2024–2029
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $222.9K · Beckman Research Institute/City of Hope
1997–2027
City of Hope Lymphoma SPORE
National Cancer Institute · P50
Project lead · $336.8K · Beckman Research Institute/City of Hope
2018–2023

Clinical trials

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 1
City of Hope Medical Center
2023–2028
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 2
City of Hope Medical Center
2021–2027
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 2
City of Hope Medical Center
2021–2029
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Principal investigator · Active not recruiting · Phase 2
City of Hope Medical Center
2021–2027